The prognostic value of @entity172 receptors ( @entity1782 and @entity1783 ) mRNA expression in @entity1 with @entity1149 ( @entity1149 ) remains controversial. Therefore, a systematic review with meta-analysis was conducted. A systematic literature search was conducted in both Pubmed and Embase. Studies that reported association of ESR and survival in @entity1149 @entity1 in the form of hazard ratio (HR) and 95% confidence interval (CI) were included. Pooled HR was taken as the effect size to reflect the association. Five eligible articles provided six separate studies for @entity1782 and four for @entity1783 . For @entity1782 , the pooled HR of overall survival was 0.72 (95% CI 0.41-1.27) by univariate analysis and was 0.33 (95% CI: 0.20-0.53) by multivariate analysis. For @entity1783 , the pooled HR was 0.95 (95% CI 0.73-1.23) by univariate analysis. Sub-group analysis suggested that the disease stages and cut-off point may explain heterogeneity among studies of @entity1782 . Results of the meta-analysis revealed a potential benefit of positive @entity1782 mRNA expression in survival in @entity1 with @entity1149 , especially in those of advanced stage. No statistically significant association was found between @entity1783 mRNA expression and @entity1149 @entity1 ' prognosis.

Prognostic value of XXXX receptors mRNA expression in @entity1149 : A systematic review and meta-analysis.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity1782 :: ('2099', 'Gene') :: ['ESR1'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity1783 :: ('2100', 'Gene') :: ['ESR2']
@entity172 :: (MESH:D004967,Chemical) :: ['estrogen']
